Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Property, Plant & Equipment (Net) · Q2 FY2026 · quarter ended Jun 2026
Property, plant & equipment (net) of $6.92M in Q2 FY2026
Q2 FY2026 property, plant & equipment (net) was $6.92M.
Context
- Property, plant & equipment (net) amounted to 5.4% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 7.87M USD
- Year-over-year change
- +143.2%
- 1-year CAGR
- +143.2%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.87M | +143.2% |
| FY2024 | 2024-12-31 | 3.23M | — |
Property, Plant & Equipment (Net) vs competitors
How ATTO compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Property, plant & equipment (net) amounts to 5.4% of total assets for ATTO, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | Jun 2026 | $34.12M USD | -11.5% | +98.8% | 6.1% |
| Mar 2026 | $13.32M USD | -15.0% | -11.4% | 4.0% | |
EVMNEvommune, Inc. | Mar 2026 | $9.57M USD | +573.5% | — | 3.0% |
| Jun 2026 | $6.92M USD | — | — | 5.4% | |
| Mar 2026 | $5.83M USD | -14.6% | -12.8% | 9.1% | |
| Dec 2025 | $4.46M USD | +5.1% | -6.1% | 7.9% | |
ORKAOruka Therapeutics, Inc. | Sep 2026 | $3.1M USD | +39.3% | +79.2% | 0.3% |
| Mar 2026 | $2.89M USD | +206.5% | — | 1.5% | |
| Mar 2026 | $2.39M USD | -27.6% | +86.2% | 0.6% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €1.68M EUR | — | — | 1.0% |
ZURAZura Bio Limited | Mar 2026 | $125K USD | +17.9% | — | 0.1% |
| Peer median (excluding ATTO) | — | +5.1% | +36.6% | 2.2% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 30.63M | 40.19M |
| Short-term Investments | 38.69M | 112.08M |
| Net Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 3.16M | 4.03M |
| Total Current Assets | 72.48M | 156.3M |
| Property, Plant & Equipment (Net) | 3.23M | 7.87M |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 607K | 404K |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 393K | 1.33M |
| Total Non-current Assets | 4.23M | 9.6M |
| Total Assets | 76.72M | 165.89M |
| Account Payables | 4.14M | 3.55M |
| Short-term Debt | 0 | 1.92M |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 0 | 450K |
| Other Current Liabilities | 1.52M | 1.98M |
| Total Current Liabilities | 7.72M | 11.01M |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 6.87M | 755K |
| Total Non-current Liabilities | 6.87M | 4.1M |
| Total Liabilities | 14.59M | 15.1M |
| Common Stock | 1K | 1K |
| Retained Earnings | (50.38M) | (111.01M) |
| Accumulated OCI | 67K | 99K |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | 62.13M | 150.79M |
| Total Debt | 0 | 5.26M |
| Net Debt | (30.63M) | (34.93M) |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.